Introduction {#Sec1}
============

The protective properties of strontium salts on bone were first suggested in 1959 when strontium lactate was reported to decrease bone pain in a small study of osteoporotic patients and increase bone density radiographically \[[@CR1]\]. Following the report that strontium ranelate reduced vertebral fracture in osteoporotic postmenopausal women, it has been widely used in the treatment of osteoporosis. While the anti-fracture efficacy of strontium has been well established \[[@CR2], [@CR3]\], the fundamental ways in which it acts on bone components remain unclear.

Following the observation that dietary supplementation with strontium chloride increased osteoid surface and decreased osteoclast numbers in mice \[[@CR4]\], the notion that strontium can act as a direct 'uncoupler' of bone turnover, enhancing bone formation and decreasing resorption, has become well established \[[@CR5]--[@CR7]\]. Studies with cultured primary cells indicated that strontium increased the proliferation of pre-osteoblasts \[[@CR8]\] and also osteoblast differentiation and mineralisation \[[@CR7], [@CR9], [@CR10]\]. Activation of the calcium-sensing receptor is reported to be a key pathway mediating beneficial actions of strontium on osteoblasts, such as increased proliferation \[[@CR11], [@CR12]\], inhibition of prostaglandin-mediated apoptosis \[[@CR12]\] and increased nuclear translocation of β-catenin \[[@CR13]\]. Strontium is also reported to increase Wnt signalling in osteoblasts \[[@CR10]\] and to promote osteoblastogenesis through nuclear factor kappa B (NF-κB) blockade \[[@CR14]\]. Strontium may reduce osteoclast activity by disrupting ruffled border formation \[[@CR15]\] or the 'sealing zone' substrate contact \[[@CR7]\]. Strontium is additionally reported to reduce osteoclast formation \[[@CR7]\] and may cause osteoclast apoptosis via an NF-κB-mediated pathway, albeit at very high concentrations \[[@CR16], [@CR17]\].

Strontium has also long been known to exert physicochemical effects on hydroxyapatite mineral, increasing its solubility \[[@CR18]--[@CR20]\]. Moreover, strontium causes osteomalacia in a rat model of chronic renal failure \[[@CR21]\] and is associated with osteomalacia in dialysis patients \[[@CR22]\]. In normal monkeys, however, strontium treatment was reported to have no significant effect on bone mineral \[[@CR23]\].

In view of the continuing debate over the actions of strontium on bone and the lack of congruent studies that have assessed the direct effects of strontium on the ultimate physiological functions of osteoblasts and osteoclasts, namely bone formation and mineralised tissue resorption, we performed the present investigation. The primary aims of this study were to determine the effects of physiologically relevant concentrations of strontium salts on (1) the formation and mineralisation of bony structures ('nodules') in primary cultures of rat osteoblasts and (2) the formation and resorptive activity of osteoclasts in mouse marrow cultures.

Materials and methods {#Sec2}
=====================

Reagents {#Sec3}
--------

Dulbecco's modified Eagle's medium and foetal calf serum were purchased from (Gibco, Paisley, UK); macrophage colony-stimulating factor (M-CSF), receptor activator of NF-κB ligand (RANKL) and prostaglandin E~2~ were from R&D Systems Europe (Abingdon, UK). Other reagents were from Sigma-Aldrich (Poole, UK), except where otherwise stated.

Primary osteoblast culture {#Sec4}
--------------------------

Bone-forming, primary rat osteoblastic cells were obtained by sequential enzyme digestion of excised calvarial bones from 2-day-old neonatal Sprague Dawley rats using a three-step process, as previously described \[[@CR24], [@CR25]\]. Briefly, bones were treated with 1 % trypsin in phosphate-buffered saline (PBS) for 10 min, 0.2 % collagenase type II in Hank's balanced salt solution (HBSS) for 30 min, then 0.2 % collagenase type II in HBSS for 60 min. The first two digests were discarded and the cells from the final digest resuspended in Dulbecco's modified essential medium supplemented with 10 % foetal calf serum (FCS), 2 mM [l]{.smallcaps}-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 0.25 μg/ml amphotericin (complete mixture abbreviated to 'DMEM'). Cells were cultured for 2--4 days in a humidified atmosphere of 5 % CO~2~-95 % air at 37 °C in 75-cm^2^ flasks until confluent. Upon confluence, cells were subcultured into multiwell plates in 'supplemented' DMEM containing dexamethasone (10 nM), β-glycerophosphate (2 mM) and ascorbate (50 μg/ml). Cells were then cultured for 14 days in the absence or presence of 1 μm--1 mM strontium chloride or ranelate, with half medium changes every 3 days. Medium pH, pO~2~ and pCO~2~ were controlled throughout.

At 14 days, cell layers were fixed in 2 % glutaraldehyde for 5 min and washed with 70 % ethanol prior to drying. Plates were imaged at 2,000 dots/cm^2^ using a high-resolution flatbed scanner (Perfection Photo 3200; Epson UK, Hemel Hempstead, UK). Binary images of each well were analysed using constant threshold and minimum particle levels (ImageJ software, National Institutes of Health), allowing measurement of the numbers bone nodules formed and their plan surface area.

Primary osteoclast culture {#Sec5}
--------------------------

Osteoclast-forming marrow mononuclear cells were obtained by flushing the long bones of two 6--8-week-old MF1 mice using a 25-gauge needle, as previously described \[[@CR26]\]. After washing in PBS, marrow cells were initially cultured for 24 h at 37 °C in 5 % CO~2~ in 75-cm^2^ flasks in minimal essential medium (MEM) supplemented with 10 % FCS, 2 mM [l]{.smallcaps}-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin B and 100 nM prostaglandin E~2~ (PGE~2~) (abbreviated 'supplemented MEM') containing 2.5 ng/ml M-CSF. Non-adherent cells were collected and resuspended at 5 × 10^6^ cells/ml in supplemented MEM containing 10 ng/ml M-CSF and 3 ng/ml RANKL. Two-hundred-microlitre samples of cell suspension (10^6^ cells) were allowed to sediment for 24 h onto 5-mm-diameter dentine discs (elephant ivory kindly donated by HM Revenue and Customs, Heathrow Airport, UK) in 96-well trays at 37 °C to allow the attachment of osteoclast precursors. Dentine discs were then transferred to six-well trays containing supplemented MEM with 10 ng/ml M-CSF and 3 ng/ml RANKL. Cells were cultured for 8 days in 5 % CO~2~ with 0--1 mM of strontium ranelate or chloride. For the final 2 days of culture, the medium pH was reduced from 7.4 to 7.0 by addition of HCl in order to activate resorption pit formation by mature osteoclasts formed.

Experiments were terminated by washing discs in PBS followed by fixation in 2.5 % glutaraldehyde for 5 min. Discs were stained for tartrate-resistant acid phosphatase (TRAP) using a leucocyte acid phosphatase kit. Osteoclasts were identified as TRAP-positive multinucleated cells; numbers of osteoclasts, area resorbed and, thus, activity per osteoclast were evaluated blindly using transmitted and reflected light microscopy, respectively, on coded discs, as described previously \[[@CR26]\].

Determination of alkaline phosphatase activity {#Sec6}
----------------------------------------------

Osteoblast alkaline phosphatase activity was measured in cell lysates after 4, 7, 10 and 14 days in culture using a colorimetric kit, as previously described \[[@CR24]\].

Cell number and viability assay {#Sec7}
-------------------------------

Cell numbers were measured at 3, 7, 10 and 14 days after seeding osteoblasts at 2.5 × 10^4^ cells/well into 24-well plates, using a colorimetric kit (CytoTox 96®; Promega UK, Southampton, UK) which quantifies cellular lactate dehydrogenase (LDH) activity, as previously described \[[@CR27]\]. Briefly, cells were lysed with 1 % Triton X-100 in water (lysis buffer, 15 μl/ml of medium) for 1 h. The culture medium supernatant and cell lysate LDH content were measured independently (ELx800 plate reader; BioTek International) according to the manufacturer's instructions, using a standard curve derived from cells seeded between 10^2^ and 10^6^/well. Cell viability was estimated as the ratio of total cellular LDH to culture medium LDH.

Ionised Ca^2+^ and pH assessment {#Sec8}
--------------------------------

Ionised calcium and pH were measured in 300-μl medium samples of culture medium using a blood gas analyser (Radiometer 705; Radiometer, Crawley, UK).

Statistical analysis {#Sec9}
--------------------

Experimental data were analysed using one-way ANOVA using the Bonferroni method to correct for multiple comparisons. Results are presented as the mean ± standard error of the mean (SEM) for six replicates.

Results {#Sec10}
=======

Strontium salts inhibit bone mineralisation in vitro {#Sec11}
----------------------------------------------------

Control cultures of rat osteoblasts formed abundant nodules and trabecula-like structures of mineralised bone matrix after 14 days. Strontium ranelate (SrR) reproducibly caused a strong, dose-dependent inhibition of mineralisation, with near-total blockade observed at a concentration of 0.1 mM. However, production of collagenous matrix structures appeared to be unaffected even in the presence of the highest concentration of strontium ranelate used (1 mM) (Fig. [1](#Fig1){ref-type="fig"}). At concentrations of 0.01, 0.1 and 1 mM, SrR elicited 59, 98 and 100 % inhibitions of mineralisation of control values, respectively. Strontium chloride (SrCl~2~) also inhibited mineralisation strongly, causing 34, 95 and 100 % reductions at the same concentrations (Fig. [2a](#Fig2){ref-type="fig"}). Strontium salts caused a corresponding increase in the retention of ionised calcium in the osteoblast culture medium. After 14 days of treatment with 1 mM SrR or SrCl~2~, the measured calcium concentration in the culture medium was the same as that in the medium from undifferentiated day 3 cultures in which the control osteoblasts had yet to begin mineralising (i.e. about 1 mM). Medium pH in strontium-treated cultures remained close to the control value (Fig. [2b](#Fig2){ref-type="fig"}).Fig. 1Strontium ranelate (*SrR*) blocks bone matrix mineralisation in 14-day primary cultures of rat osteoblasts. *Upper row images* are reflected light scans of unstained cell wells; mineralised bone nodules appear as *white features*; *scale bar* = 0.5 cm. *Lower row images* are corresponding phase contrast (transmitted light) micrographs of unstained cell layers; mineralised bone nodules appear as *black features*, and unmineralised collagenous matrix is *white-grey*; *scale bar* = 0.5 mmFig. 2**a** Dose-dependent inhibition of mineralised bone formation in 14-day rat osteoblast cultures by strontium salts. Strontium ranelate (SrR) caused near-total blockade at concentrations ≥0.1 mM; strontium chloride (SrCl~2~) completely blocked mineralisation at a concentration of 1 mM. **b** Strontium salts caused a corresponding increase in the retention of ionised calcium in the culture medium of bone-forming osteoblasts; the measured concentration of ionised Ca^2+^ in the culture medium at day 3 (i.e. before onset of osteoblast differentiation and mineral deposition) was 1.03 mM. Culture medium pH remained within 0.01 unit of the control value. pH was corrected for CO~2~ concentration. Data are means ± SEM for six replicate determinations; \*\*\**p* \< 0.001, significantly different from control

A moderate reduction of osteoblast alkaline phosphatase (ALP) activity was observed in 14-day cultures treated with SrCl~2~; smaller decreases were also seen in SrR-treated cultures (Fig. [3a](#Fig3){ref-type="fig"}). In parallel, strontium salts caused increases in lactate dehydrogenase release from cells, an index of cell morbidity/mortality, although estimated cell numbers were not significantly affected (Fig. [3b](#Fig3){ref-type="fig"}).Fig. 3**a** Effect of strontium salts on alkaline phosphatase (ALP) activity in 14-day rat osteoblast cultures: modest inhibition by SrCl~2~. **b** Strontium salts were also associated with moderate decreases in cell viability, assessed as lactate dehydrogenase activity, although cell numbers were not affected. Data are means ± SEM for six replicate determinations; \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001, significantly different from control

Strontium salts inhibit osteoclast numbers and resorption pit formation {#Sec12}
-----------------------------------------------------------------------

Continuous treatment with strontium salts caused reductions of up to about 50 % in the total surface area of resorption pits and in the numbers of multinucleated osteoclasts present on ivory discs in 8-day cultures of mouse marrow cells. However, the area resorbed by individual osteoclasts was not significantly reduced (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}).Fig. 4Strontium ranelate causes a moderate inhibition of numbers of multinucleated osteoclasts observed in mouse marrow mononuclear cells cultured for 8 days on ivory discs with M-CSF and RANKL. TRAP-stained preparation; resorption pits are visible as *tan areas* associated with osteoclasts. *Scale bar* = 100 μmFig. 5**a** Strontium salts cause a moderate inhibition of resorption pit formation by osteoclasts generated in 8-day cultures of mouse marrow cells on ivory discs. **b** Strontium salts were associated with corresponding decreases in numbers of multinucleated, TRAP-stained osteoclasts. **c** The resorptive activity of individual osteoclasts was not affected by strontium salts. Data are means ± SEM for eight replicate determinations; \**p* \< 0.05; \*\*\**p* \< 0.001, significantly different from control

Discussion {#Sec13}
==========

Strontium ranelate has been regarded as an anti-osteoporotic drug that can shift the balance between bone resorption and bone formation towards the latter. However, the mechanisms by which strontium exerts its effects on bone have remained relatively unclear \[[@CR28]\]. Our results clearly demonstrate that strontium salts have two direct effects on bone cell function in vitro. Their major action is to cause potent inhibition of mineral deposition in bone-forming cultures of primary osteoblasts. Secondly, strontium salts cause moderate reductions in osteoclast numbers and, thus, resorption pit formation in mouse marrow cultures on dentine surfaces.

Mineralisation in bone-forming osteoblast cultures was dose-dependently reduced by strontium salts, with partial or near-complete inhibition at 0.01 and 0.1 mM, respectively. The strontium-treated cultures showed a striking and corresponding increase in the presence of unmineralised matrix nodules. The observed inhibition of mineralisation by strontium salts at micromolar concentrations in primary rat osteoblast cultures is in broad agreement with the earlier findings of Verberckmoes et al. \[[@CR29]\]. We also failed to observe any clear-cut effect of strontium on osteoblast numbers (although an apparent reduction in cell viability was noted in strontium-treated cultures). In contrast, we found a modest inhibitory effect of strontium chloride at submillimolar concentrations on osteoblast alkaline phosphatase activity. These findings are at variance with those of several other studies on the action of strontium ranelate in calvarial osteoblast cultures. Acute stimulation of proliferation of rat osteoblasts was described following exposure to high concentrations (1--5 mM) of SrR \[[@CR8], [@CR11]\]. Increased calcification and expression of alkaline phosphatase mRNA were reported for mouse osteoblasts treated chronically with 0.1--1 mM strontium ranelate \[[@CR7]\]. In the MC3T3-E1 cell line, however, strontium ranelate treatment increased the strontium content of deposited mineral but failed to increase calcification \[[@CR30]\]. The discrepancies between the above findings could, to some extent, be accounted for by significant differences in osteoblast culture methods. The key advantage of the culture system employed in the present study is the formation of abundant bony structures that resemble trabeculae, with clearly distinguished mineralised and non-mineralised components \[[@CR24], [@CR25]\].

Our study showed that strontium ranelate was a significantly more effective inhibitor of mineralisation on a molar basis than strontium chloride. This discrepancy in potency may well be due to the differing stoichiometry of these two strontium salts. Ranelate chelates two strontium ions per molecule, whereas the chloride salt has only a single strontium ion. However, it is possible that the ranelate component of strontium ranelate may also have an independent calcium ion-chelating action that could affect mineralisation. The inhibition of mineralisation in strontium-treated osteoblast cultures was reflected in increased retention of ionised calcium in the culture medium. It should be noted that this calcium retention was of a lower relative magnitude than the degree of inhibition of mineralisation. This apparent inconsistency is explained by the changes of culture medium that were made every 3--4 days. Studies by Verberckmoes et al. \[[@CR31]\], using mineralising cultures of osteoblast-like UMR-106 cells and synthetic calcium hydroxyapatite doped with increasing concentrations of strontium, have suggested that strontium inhibits mineralisation via two physicochemical effects: first, direct inhibition of crystal growth and, secondly, increased solubility of calcium hydroxyapatite.

The action of strontium salts on osteoclast function was much less marked than on osteoblasts and mineralisation. At the highest concentration tested (1 mM), strontium caused 33--50 % reductions in both osteoclast numbers and resorption pit formation, suggesting that it had little or no direct effect on osteoclast activity (i.e. resorption pit formation). The reduced numbers of osteoclasts observed in strontium-treated cultures could be due either to reduced formation or reduced survival or both. Previous studies have noted reductions in osteoclast numbers in cultures treated with strontium salts at concentrations up to 24 mM \[[@CR7], [@CR17]\]; these very high concentrations are well outside the in vivo range, however.

The strontium concentrations used in the present study spanned the levels measured in the blood of treated individuals (0.02 mM) \[[@CR32]\]. However, there is a clear discrepancy between our in vitro findings and the results of the major clinical trials of strontium ranelate, which showed decreased fracture risk associated with increases in bone mineral density of between 7.2 and 14.4 % after prolonged treatment \[[@CR2], [@CR33]\]. It should be noted, though, that a significant component of the increased bone mineral density measured in strontium-treated patients could be due to the incorporation of strontium, which has more than twice the atomic mass of calcium; a 1 % molar concentration of strontium has been shown to cause a 10 % overestimation of BMD \[[@CR34]\]. In contrast to the reported increases in bone mineral density, strontium-induced osteomalacia has been described in rats with chronic renal failure \[[@CR21], [@CR35]\]. Strontium levels in blood and bone have been linked to osteomalacia in human patients undergoing haemodialysis in some studies \[[@CR22], [@CR36]\].

The key limitation of our study is that it was conducted in vitro using rodent cells. However, cell or organ cultures represent the only practicable way to study the direct effects of strontium on bone cells, free of the confounding influences present in vivo. The use of rodent osteoblasts was necessitated because primary human osteoblasts (at least from adults) have not been shown to be capable of true bone formation in vitro. Clearly, caution is needed when relating tissue culture results to the in vivo situation. Nevertheless, our findings do suggest a number of testable ideas. The first is that long-term strontium treatment might act to reduce fracture risk because it could reduce the secondary hypermineralisation that occurs in low-turnover bone, thus decreasing stiffness and reducing brittleness \[[@CR37]\]. Similarly, strontium treatment, which is reported to be protective against some forms of osteoarthritis \[[@CR38], [@CR39]\], might act to reduce secondary mineralisation of subchondral bone, making it less stiff. It is also conceivable that strontium could affect the progression of the tidemark zone of mineralisation in articular cartilage. A further possibility is that strontium treatment might act to modulate the infilling of osteocyte lacunae resulting from hypermineralisation \[[@CR40]\].

Widespread use of strontium ranelate has now been discontinued in most countries, following recent recommendations concerning its potential cardiovascular risk, although this remains somewhat controversial \[[@CR41]\]. It is nonetheless important that the mechanisms of action of strontium on bone are better understood---not only for patients already treated but also because new therapeutic directions could be suggested, particularly with regard to the control of mineralisation.
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